There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles Kyriakos Vorkas, MD, an infectious diseases physician-scientist at the Renaissance School of Medicine (RSOM) at Stony Brook University, and colleagues identified a novel population of immune cells that could serve as an alternative target for TB vaccines and immune-directed therapy. Their findings are detailed in a paper published in Scientific Reports.
Novel immune cell population may offer alternative target for tuberculosis vaccines
